DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Sofinnova Partners
Sofinnova Partners
Sofinnova Partners invests in life sciences innovation worldwide, from biopharma and medtech to digital medicine and industrial biotech.
both early and growth/opportunity families, reported GAV $1,593M
Importance
69
high
Active deployment
55
elevated
Emerging
0
low
Completeness
81
high
Freshness
100
high
Research priority
20
moderate
Identity and regulatory footprint
- Headquarters
- Paris, Franceadviserinfo.sec.gov
- Office address
- 7-11 BD HAUSSMANN, Paris, 75009adviserinfo.sec.gov
- Business phone
- 0033176234100adviserinfo.sec.gov
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- private fund adviseradviserinfo.sec.gov
- Latest Form ADV
- Mar 28, 2024
- Private funds reported
- 15 (14 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $1.6Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Owners on Schedule A
- Société Civile Montclair (Société Civile), E; APO Nova Holdings L.P. (Minority Shareholder), B
- business phone
- 0033176234100adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
149 observed deals
Stated (the firm’s website)
- Sectors
- healthcare, biotech, medtech, climate, industrial, agtech
- Stages
- seed, growth, early
- Geography
- europe
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- venture capital
Observed (from deals on record)
Stage at participation
series c 100%
Stage at first entry
series c 100%
Sectors
unknown 99%Biotechnology 1%
lead rate 100%follow-on rate 0%new logos, 12 months 148
Funds and vehicles
15 reported, 2 no longer reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Sofinnova Digital Medicine I | Fund | 2023 adv first reported | Active deployment | $41.9M Mar 28, 2024 | 40 | unknown | unknown |
| Sofinnova Capital X | Fund | 2022 adv first reported | Active deployment | $113M Mar 28, 2024 | 57 | unknown | unknown |
| Sofinnova Industrial Biotech II | Fund | 2022 adv first reported | Active deployment | $38.6M Mar 28, 2024 | 35 | unknown | unknown |
| Sofinnova MD Start III | Fund | 2020 adv first reported | Mature | $99.8M Mar 28, 2024 | 29 | unknown | unknown |
| Sofinnova Coiv Eif | Fund | 2020 adv first reported | Mature | $12.1M Mar 28, 2024 | 2 | unknown | unknown |
| Sofinnova Crossover I | Growth fund · ADV: Private Equity Fund | 2019 adv first reported | Mature | $324M Mar 28, 2024 | 60 | unknown | unknown |
| Sofinnova Capital Ix | Fund | 2019 adv first reported | Mature | $222M Mar 28, 2024 | 44 | unknown | unknown |
| Sofinnova Telethon Sca Raif | Fund | 2019 adv first reported | Mature | $66.7M Mar 28, 2024 | 23 | unknown | unknown |
| Sofinnova IT | Fund | 2019 adv first reported | Mature | $53.5M Mar 28, 2024 | 4 | unknown | unknown |
| Sofinnova Industrial Biotech I | Fund | 2018 adv first reported | Harvest | $106M Mar 28, 2024 | 21 | unknown | unknown |
| Sofinnova Capital Viii | Fund | 2016 adv first reported | Harvest | $271M Mar 28, 2024 | 34 | unknown | unknown |
| Sofinnova Capital VII | Fund | 2013 adv first reported | Harvest | $112M Mar 28, 2024 | 36 | unknown | unknown |
| Sofinnova Green Seed Fund | Seed fund | 2013 adv first reported | Harvest | $48.9M Mar 28, 2024 | 18 | unknown | unknown |
| Sofinnova Capital VI | Fund | unknown | Unknown | $78.4M Mar 28, 2024 | 64 | unknown | unknown |
| Sofinnova Capital V | Fund | unknown | Unknown | $4.9M Mar 28, 2024 | 77 | unknown | unknown |
| Sofinnova Capital IV | Fund | unknown | Wound down | $20.0M Jun 21, 2019 | 75 | unknown | unknown |
| Sofinnova Capital III | Fund | unknown | Wound down | $1.3M Apr 7, 2017 | 55 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
72 current, 3 departed
Antonin Weckel
AnalystAnalyst, Sofinnova Partners – Capital Strategy
Elliott Puttock
AnalystAnalyst, Sofinnova Partners – Crossover Strategy
Gabriela Sachet Fernandez
AnalystAnalyst, Sofinnova Partners - Industrial Biotech Strategy
Nicolas Tuvi
AnalystAnalyst, Sofinnova Partners
Aishwarya Parthasarathy
AssociateAssociate, Sofinnova Partners - Digital Medicine Strategy
Anna Belousova
AssociateAssociate, Sofinnova Partners - Industrial Biotech Strategy
Daniel Sieiro
AssociateAssociate, Sofinnova Partners - Capital Strategy
Mariam Cherifi
AssociateAssociate, Sofinnova Partners - Industrial Biotech Strategy
Monique Saulnier
Board or advisorySenior Advisor, Sofinnova Partners
Ahmed Fourati
Investor relationsInvestor Relations and Reporting Officer, Sofinnova Partners
Aziliz Le Roux
Investor relationsInvestor Relations Manager, Sofinnova Partners
Nathalie Loreaux
Investor relationsInvestor Relations and Reporting Manager, Sofinnova Partners
Sara Saoud
Investor relationsInvestor Relations Analyst, Sofinnova Partners
Antoine Papiernik
Managing partnerChairman & Managing Partner, Sofinnova Partners
Antoine Papiernik
Managing partnerManaging Partner And Chairman · since Nov 1, 2000
Graziano Seghezzi
Managing partnerManaging Partner, Sofinnova Partners
Graziano Seghezzi
Managing partnerManaging Partner · since Apr 1, 2012
Henrijette Richter
Managing partnerManaging Partner, Sofinnova Partners
Henrijette Richter
Managing partnerManaging Partner · since Sep 1, 2014
Monique Saulnier
Managing partnerFormer Managing Partner Of Sofinnova Partners · since Oct 1, 2023
United Purpose
OtherManaging Partners
Alex Leech
PartnerPartner, Sofinnova Partners - Biovelocita Strategy
Anne Osdoit
PartnerPartner, Sofinnova Partners - MD Start Strategy
Anta Gkelou
PartnerPartner, Sofinnova Partners - Capital Strategy
Cedric Moreau
PartnerPartner, Sofinnova Partners - Crossover Strategy
David Evans
PartnerPartner
Edward Kliphuis
PartnerPartner, Sofinnova Partners - Digital Medicine Strategy
Enzo Petrelluzzi
PartnerProject Manager, Sofinnova Partners
Gabriella Camboni
PartnerPartner, Sofinnova Partners - Biovelocita Strategy
Guillaume Baxter
PartnerPartner, Sofinnova Partners - Industrial Biotech Strategy
Jacques Theurillat
PartnerPartner, Sofinnova Partners - Crossover Strategy
Joe Anderson
PartnerPartner, Sofinnova Partners - Crossover Strategy
Karl Naegler
PartnerPartner, Sofinnova Partners – Capital Strategy
Kinam Hong
PartnerPartner, Sofinnova Partners - Crossover Strategy
Ligia Vela-Reid
PartnerCommunication Manager, Sofinnova Partners
Lucia Faccio
PartnerPartner, Sofinnova Partners - Telethon Strategy
Maina Bhaman
PartnerPartner, Sofinnova Partners - Capital Strategy
Mano Iyer
PartnerPartner, Sofinnova Partners - MD Start Strategy
Matthieu Coutet
PartnerPartner, Sofinnova Partners - Biovelocita Strategy
Michael Krel
PartnerPartner, Sofinnova Partners - Industrial Biotech Strategy
Michael Krel
PartnerPartner
Paola Pozzi
PartnerPartner, Sofinnova Partners - Telethon Strategy
Pauline Roca
PartnerOffice & Travel Manager, Sofinnova Partners
Simon Turner
PartnerPartner, Sofinnova Partners - Digital Medicine Strategy
Zhizhong Joel Yao
PartnerPartner, Sofinnova Partners - Biovelocita Strategy
Armance Bordes
Platform and operationsGeneral Counsel and Head of Legal & Compliance, Sofinnova Partners
Bommy Lee
Platform and operationsHead of Communications, Sofinnova Partners
Christophe Blanche
Platform and operationsChief Financial Officer, Sofinnova Partners
Estelle Rigaux
Platform and operationsSenior Compliance Officer - RCCI, Sofinnova Partners
Hortense Fouilland
Platform and operationsLegal Counsel, Sofinnova Partners
Johanna Guacide
Platform and operationsFunds Accounting Manager, Sofinnova Partners
Julia Metzger
Platform and operationsExecutive Assistant, Sofinnova Partners
Juliette Grant
Platform and operationsExecutive Assistant, Sofinnova Partners
Lamia Verney
Platform and operationsExecutive Assistant, Sofinnova Partners
Mats Kristian Eklund
Platform and operationsChief Operating Officer And Directeur General · since Oct 1, 2022
Pamela Putz
Platform and operationsEvents and Community Manager, Sofinnova Partners
Paola Pizzi
Platform and operationsHead of Operations, Italy, Sofinnova Partners
Perrine Soupault
Platform and operationsSenior Legal Counsel, Sofinnova Partners
Sandrine Le Penru
Platform and operationsExecutive Assistant, Sofinnova Partners
Sylvie Chapoy
Platform and operationsExecutive Assistant, Sofinnova Partners
Thomas Bermudes
Platform and operationsSenior Legal Counsel, Sofinnova Partners
Javier Nunez-Vicandi
PrincipalPrincipal, Sofinnova Partners - Digital Medicine Strategy
Marion Gasperment
PrincipalPrincipal, Program Manager, Sofinnova Partners - MD Start Strategy
Tiziana Rossetti
PrincipalPrincipal, Sofinnova Partners - Telethon Strategy
Andrew M. Weiss
Venture partnerVenture Partner, Sofinnova Partners
Josh Makower
Venture partnerVenture Partner, Sofinnova Partners
Martin T. Rothman
Venture partnerVenture Partner, Sofinnova Partners
Silvano Spinelli
Venture partnerVenture Partner, Sofinnova Partners
Ankeet Jethwa
Vice presidentSenior Associate, Sofinnova Partners - Capital Strategy
Aseem Ghaghda
Vice presidentSenior Associate, Sofinnova Partners - Capital Strategy
Claire Catherinet
Vice presidentSenior Associate, Sofinnova Partners - Crossover Strategy
Cristina Pelizon
Vice presidentSenior Associate, Program Manager, Sofinnova Partners - Biovelocita Strategy
3 departed (kept with end dates)
- Rafaele Tordjman · Managing Partner · Nov 1, 2000 to Jun 16, 2020 Inference
- Jean Bernard Schmitt · Retired · Jul 1, 1997 to Jun 16, 2020 Inference
- Denis Lucquin · Partner · Jul 1, 2021 to Oct 17, 2022 Inference
Investments on record
149 edges, 148 companies, 2 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
20 relationships from shared deals, counted for the whole firm
Sofinnova Investments, Inc. 2 shared · recurringFuture Planet Capital Limited 1 shared · one timeAndera Partners 1 shared · one timeMedtronic 1 shared · one time · we led 1Omega Fund Management, LLC 1 shared · one timeSprig Equity Management, LLC 1 shared · one time · we led 1Vivo Capital, LLC 1 shared · one timeElm Street Ventures 1 shared · one time · we led 1Clark Partners 1 shared · one time · we led 1Emerald Technology Ventures 1 shared · one time · we led 1Connecticut Innovations 1 shared · one time · we led 1BASF 1 shared · one time · we led 1Chanel 1 shared · one time · we led 1Invus 1 shared · one time · we led 1Deep Track Capital 1 shared · one time · we led 1Maj Invest Equity 1 shared · one time · we led 1Novo Holdings 1 shared · one time · we led 1Avoro Ventures 1 shared · one time · we led 1Access Biotechnology 1 shared · one time · we led 1HealthCap 1 shared · one time · we led 1
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
27 dated events
- Mar 22, 2023Sofinnova Digital Medicine I first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $22,570,567Fund first reported on Form ADVFundsFactSofinnova Digital Medicine ISEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Oct 17, 2022Denis Lucquin (Partner) no longer on Schedule A of Sofinnova Partners
- Oct 1, 2022Mats Kristian Eklund joined Schedule A of Sofinnova Partners as Chief Operating Officer
- Mar 30, 2022Sofinnova Capital X first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $21,228,416Fund first reported on Form ADVFundsFactSofinnova Capital XSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2022Sofinnova Industrial Biotech II first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $23,558,987Fund first reported on Form ADVFundsFactSofinnova Industrial Biotech IISEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jun 16, 2020Sofinnova Coiv Eif first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $3,184,112Fund first reported on Form ADVFundsFactSofinnova Coiv EifSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jun 16, 2020Jean Bernard Schmidt (Retired) no longer on Schedule A of Sofinnova Partners
- Jun 16, 2020Rafaele Tordjman (Managing Partner) no longer on Schedule A of Sofinnova Partners
- Jun 16, 2020Sofinnova Capital IV no longer reported on Form ADV by Sofinnova PartnersFund no longer reportedFundsInferenceSofinnova Capital IVSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jun 16, 2020Sofinnova MD Start III first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $3,190,250Fund first reported on Form ADVFundsFactSofinnova MD Start IIISEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jun 21, 2019Sofinnova IT first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $64,000,000Fund first reported on Form ADVFundsFactSofinnova ITSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jun 21, 2019Sofinnova Capital Ix first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $15,000,000Fund first reported on Form ADVFundsFactSofinnova Capital IxSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jun 21, 2019Sofinnova Telethon Sca Raif first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $3,000,000Fund first reported on Form ADVFundsFactSofinnova Telethon Sca RaifSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jun 21, 2019Sofinnova Crossover I first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $25,000,000Fund first reported on Form ADVFundsFactSofinnova Crossover ISEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 13, 2018Sofinnova Capital III no longer reported on Form ADV by Sofinnova PartnersFund no longer reportedFundsInferenceSofinnova Capital IIISEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 13, 2018Sofinnova Industrial Biotech I first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $5,000,000Fund first reported on Form ADVFundsFactSofinnova Industrial Biotech ISEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jun 28, 2016Sofinnova Capital Viii first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $28,100,000Fund first reported on Form ADVFundsFactSofinnova Capital ViiiSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Sep 1, 2014Henrijette Richter joined Schedule A of Sofinnova Partners as Managing Partner
- Aug 30, 2013Sofinnova Capital VII first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $15,000,000Fund first reported on Form ADVFundsFactSofinnova Capital VIISEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Aug 30, 2013Sofinnova Green Seed Fund first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $3,000,000Fund first reported on Form ADVFundsFactSofinnova Green Seed FundSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- May 9, 2012Sofinnova Capital VI first reported on Form ADV by Sofnnova Partners (Venture Capital Fund), GAV $192,000,000Fund first reported on Form ADVFundsFactSofinnova Capital VISEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- May 9, 2012Sofinnova Capital V first reported on Form ADV by Sofnnova Partners (Venture Capital Fund), GAV $446,000,000Fund first reported on Form ADVFundsFactSofinnova Capital VSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- May 9, 2012Sofnnova Partners first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- May 9, 2012Sofinnova Capital III first reported on Form ADV by Sofnnova Partners (Venture Capital Fund), GAV $10,000,000Fund first reported on Form ADVFundsFactSofinnova Capital IIISEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- May 9, 2012Sofinnova Capital IV first reported on Form ADV by Sofnnova Partners (Venture Capital Fund), GAV $136,000,000Fund first reported on Form ADVFundsFactSofinnova Capital IVSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 1, 2012Graziano Seghezzi joined Schedule A of Sofinnova Partners as Managing Partner
- Apr 1, 2012Graziano Seghezzi joined Schedule A of Sofinnova Partners as Managing Partner
Classification history
- Sep 12, 2026Multi-stage venture firm (probable, 80%, cls-1)both early and growth/opportunity families, reported GAV $1,593M
Evidence
49 observations from 2 sources